Norfloxacin in Multiple Drug Resistant Typhoid Fever
DOI:
https://doi.org/10.5915/23-1-14378Keywords:
Salmonella typhi, Norfloxacin, Multiple Drug ResistanceAbstract
DOI: http://dx.doi.org/10.5915/23-1-14378
This study was undertaken to assess the efficacy of Norfloxacin and oral quinolone in multiple drug resistant salmonella typhi infections in 45 patients. All these patients received 800 mg of Norfloxacin daily for a period of two weeks. All patients had positive blood cultures for salmonella typhi and 30 patients had, in addition, high and rising titers of TO and TH antigen (>1:160).
All patients responded from day 4 to day 10 of Norfloxacin therapy. A follow-up of one year did not reveal any relapse or a carrier state in the studied group. We recommend use of Norfloxacin in chloramphenicol resistant salmonella typhi infections.
Downloads
Published
1991-01-01
Issue
Section
Original Articles
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
